Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation

Hematology. American Society of Hematology. Education Program - Tập 2010 Số 1 - Trang 368-376 - 2010
Meinolf Suttorp1, Frédéric Millot2
1Division of Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany;
2Pediatric Oncology Unit, University Hospital, Poitiers, France

Tóm tắt

AbstractAllogeneic hematopoietic stem cell transplantation (allo-SCT) remains the only proven cure for chronic myeloid leukemia (CML), a rare malignancy in childhood. With the excellent results induced by the tyrosine kinase inhibitor (TKI) imatinib in adults in the last decade, the appropriate management of children with CML has also changed radically, and only a minority are now transplanted as a front-line treatment. Data on pediatric experiences with imatinib in CML from controlled trials remain very limited, but this review of available data describes the role of imatinib in children with CML, addressing: 1) the starting dose; 2) pharmacokinetics in childhood; 3) possible adverse effects, with a focus on the still-growing skeleton; 4) early monitoring of treatment efficacy in an attempt to avoid failure; 5) the timing of allo-SCT in children; and 6) treatment of CML relapse after allo-SCT. Because the characteristics of CML in children seem to overlap extensively with what is described in adult internal medicine, most answers and pediatric algorithms are adapted from the treatment of CML in adults. Today in 2010, allo-SCT in children should be postponed until CML becomes refractory to imatinib. The approach for young patients with suboptimal responses is unclear because data on the efficacy and safety of second-generation TKIs in childhood are almost entirely missing. Other than being included in a formal trial on second-generation TKIs, allo-SCT for patients failing imatinib remains the first choice.

Từ khóa


Tài liệu tham khảo

Ries LAG Melbert D Krapcho M SEER cancer statistics review 2008 Accessed October 6, 2010 Bethesda, MD National Cancer Institute Available from http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008

Millot, 2005, Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia, Pediatrics, 116, 140, 10.1542/peds.2004-2473

Adler, 2008, Correlation of BCR/ABL Transcript Variants with Patients' Characteristics in Childhood Chronic Myeloid Leukaemia, Eur J Haematol, 82, 112, 10.1111/j.1600-0609.2008.01170.x

Faderl, 1999, The biology of chronic myeloid leukemia, N Engl J Med, 341, 164, 10.1056/NEJM199907153410306

Claviez, 2000, Major- and/or minor bcr-abl positive chronic myeloid leukemia (CML) in six children with initial presentation as acute lymphoblastic leukemia (ALL) [Abstract], Blood, 96, 253b

Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867

Deininger, 2005, The development of imatinib as a therapeutic agent for chronic myeloid leukaemia, Blood, 105, 2640, 10.1182/blood-2004-08-3097

National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Accessed October 6, 2010 Available from: www.nccn.org/index.asp

O'Brien, 2008, International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [Abstract], Blood, 112, 186, 10.1182/blood.V112.11.186.186

Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol, 27, 6041, 10.1200/JCO.2009.25.0779

Suttorp, 2008, Innovative approaches of targeted therapy for chronic myeloid leukaemia of childhood in combination with paediatric haematopoietic stem cell transplantation, Bone Marrow Transplant, 42, S40, 10.1038/bmt.2008.282

Dow, 1991, Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia, Cancer, 68, 1678, 10.1002/1097-0142(19911015)68:8<1678::AID-CNCR2820680803>3.0.CO;2-J

Millot, 2006, Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia, Pediatr Blood Cancer, 47, 555, 10.1002/pbc.20586

Gamis, 1993, Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children, J Clin Oncol, 11, 834, 10.1200/JCO.1993.11.5.834

Cwynarski, 2003, Stem cell transplantation for chronic myeloid leukemia in children, Blood, 102, 1224, 10.1182/blood-2002-12-3637

Dini, 1996, Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European countries from the EBMT paediatric diseases working party, Bone Marrow Transplant, 18, 80

Suttorp, 2009, Allogeneic stem cell transplantation for treatment of chronic myeloid leukemia in pediatric and adolescent patients: results of the prospective trial CML-paed I, Klin Padiatr, 221, 351, 10.1055/s-0029-1239529

Millot, 2003, Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC), Bone Marrow Transplant, 32, 993, 10.1038/sj.bmt.1704255

Muramatsu, 2010, Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan marrow donor program, Biol Blood Marrow Transplant, 16, 231, 10.1016/j.bbmt.2009.09.022

Matthes-Martin, 2008, Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 14, 335, 10.1016/j.bbmt.2007.12.487

Pulsipher, 2004, Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?, Pediatr Blood Cancer, 43, 523, 10.1002/pbc.20062

Champagne, 2004, Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study, Blood, 104, 2655, 10.1182/blood-2003-09-3032

Millot, 2006, Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase, and in relapse after stem cell transplantation, Leukemia, 20, 187, 10.1038/sj.leu.2404051

Kolb, 2003, Imatinib mesylate in Philadelphia chromosome-positive leukemia in childhood, Cancer, 98, 2643, 10.1002/cncr.11895

Bond, 2008, A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study, Pediatr Blood Cancer, 50, 254, 10.1002/pbc.21132

Geoerger, 2009, Innovative Therapies for Children with Cancer European Consortium. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium, Eur J Cancer, 45, 2342, 10.1016/j.ejca.2009.03.007

Petain, 2008, On behalf of the Innovative Therapies with Children with Cancer European Consortium. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults, Clin Cancer Res, 14, 7102, 10.1158/1078-0432.CCR-08-0950

Bond, 2008, Phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study, Pediatr Blood Cancer, 50, 254, 10.1002/pbc.21132

Marangon, 2009, Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias, Cancer Chemother Pharmacol, 63, 563, 10.1007/s00280-008-0764-0

Picard, 2007, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-doseimatinib in chronic myeloid leukemia, Blood, 109, 3496, 10.1182/blood-2006-07-036012

Apperley, 2009, CML in pregnancy and childhood, Best Pract Res Clin Haematol, 22, 455, 10.1016/j.beha.2009.09.008

Hughes, 2006, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, 108, 28, 10.1182/blood-2006-01-0092

Mauro, 2009, Management of drug toxicities in chronic myeloid leukaemia, Best Pract Res Clin Haematol, 22, 409, 10.1016/j.beha.2009.06.001

Goldman, 2007, How I treat CML in the imatinib era, Blood, 110, 2828, 10.1182/blood-2007-04-038943

Kerkela, 2006, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nat Med, 12, 908, 10.1038/nm1446

Suttorp, 2008, Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure [Abstract], Blood, 112, 402, 10.1182/blood.V112.11.1100.1100

Vandyke, 2010, Dysregulation of bone remodelling by imatinib mesylate, Blood, 115, 766, 10.1182/blood-2009-08-237404

Vandyke, 2009, Imatinib mesylate causes growth plate closure in vivo, Leukemia, 23, 2155, 10.1038/leu.2009.150

Mariani, 2008, Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty, Lancet, 372, 111, 10.1016/S0140-6736(08)61023-5

Kimoto, 2009, Growth deceleration in a girl treated with imatinib, Int J Hematol, 89, 251, 10.1007/s12185-008-0251-8

Schmid, 2009, Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib, Haematologica, 94, 1177, 10.3324/haematol.2009.008359

Millot, 2009, Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial [Abstract], Blood, 110, 863, 10.1182/blood.V114.22.863.863

Tauer, 2010, Alterations of bone metabolic parameters in children and adolescents with chronic myeloid leukemia under prolonged treatment with the tyrosine kinase inhibitor imatinib [Abstract]. Proceedings of the 7th International Workshop of Musculoskeletal and Neuronal Interactions, 32

Suttorp, 2009, Chronic myeloid leukemia in pediatrics–first results from study CML-PAED II [Abstract], Blood, 114, 145, 10.1182/blood.V114.22.342.342

Lucas, 2009, Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript, Haematologica, 94, 1362, 10.3324/haematol.2009.009134

Suttorp, 2010, Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia, Haematologica, 95, 852, 10.3324/haematol.2009.019224

Hochhaus, 2009, Cause and management of therapy resistance, Best Pract Res Clin Haematol, 22, 367, 10.1016/j.beha.2009.05.004

Lahaye, 2005, Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up, Cancer, 103, 1659, 10.1002/cncr.20922

Jabbour, 2008, Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy, Blood, 112, 53, 10.1182/blood-2007-11-123950

Jabbour, 2009, Imatinib mesylate dose escalation with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy, Blood, 113, 2154, 10.1182/blood-2008-04-154344

Aplenc, 2008, Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: a report from the Children's Oncology Group Phase I consortium [Abstract], J Clin Oncol, 26, 20, 10.1200/jco.2008.26.15_suppl.3591

Horn, 2006, Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with non-malignant disorders and CML, Bone Marrow Transplant, 37, 263, 10.1038/sj.bmt.1705240

Bixby, 2009, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, Hematology Am Soc Hematol Educ Program, 461, 10.1182/asheducation-2009.1.461

Klyuchnikov, 2010, Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML), Biol Blood Marrow Transplant, 16, 301, 10.1016/j.bbmt.2009.08.019

Levine, 2008, Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population, Bone Marrow Transplant, 42, 201, 10.1038/bmt.2008.135

Simula, 2007, Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy, Leukemia, 21, 943, 10.1038/sj.leu.2404641

Burke, 2009, The treatment of pediatric Philadelphia positive leukemias in the imatinib era, Pediatr Blood Cancer, 53, 992, 10.1002/pbc.22172

Mahon, 2009, Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients, (ASH Annual Meeting Abstract) Blood, 114, 859

Russo, 2009, Phase II multicentric explorative study of intermittent imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy [Abstract], Blood, 114, 860, 10.1182/blood.V114.22.860.860

Lee, 2008, Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia, Blood, 112, 3500, 10.1182/blood-2008-02-141689

Sanders, 2005, Final adult height of patients who received hematopoietic cell transplantation in childhood, Blood, 105, 1348, 10.1182/blood-2004-07-2528

Couto-Silva, 2010, Bone markers after total body irradiation in childhood, Bone Marrow Transplant, 45, 437, 10.1038/bmt.2009.198

Perz, 2006, Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia, Haematologica, 91, 1145

Thông tin
Thông tin xuất bản

Hematology. American Society of Hematology. Education Program

Tập 2010 Số 1

368-376

Thông tin tác giả